India revokes cancer drug patent in fresh industry blow

by Penelope Macrae

India has revoked a local patent granted to Britain's GlaxoSmithKline for a breast cancer drug in the latest blow to global companies seeking a bigger presence in the country's $13 billion medicine market.

Tykerb, one of the most widely prescribed treatments in India used to treat advanced forms of the disease, is a newer version of GlaxoSmithKline's (GSK) original anti- .

The Indian patent board revoked the patent for Tykerb, calling it an incremental improvement of the original compound and not sufficiently innovative to warrant a patent.

The ruling underscores Indian authorities' tough stance against what is called "evergreening" or minor changes to a drug to extend its patent shelf life, said lawyer Dominic Alvares, part of the team which challenged GSK's Tykerb patent.

"India has some of the toughest patent laws—and they are based on public interest," Alvares, of S. Majumdar and Co, told AFP.

Once drugs go off patent, they can be sold more cheaply. India is known as the "pharmacy to the world" for its huge generics industry that turns out cheaper copycat versions of life-saving branded drugs for poor patients in developing nations.

The Tykerb ruling comes after the Supreme Court in April struck down a patent for an updated version of Swiss giant Novartis's blockbuster drug Glivec used to treat a deadly form of leukaemia.

Novartis had argued the compound was a significant improvement because it was more easily absorbed by the body but the court said it did not pass the test of innovation.

Experts then said the Novartis court ruling could pave the way for a rush of similar Indian decisions.

The latest ruling only affects GSK's newer patent, not the original patent for the main active ingredient in the drug, lapatinib, which expires in 2019.

For the first time, the patent board acted on a complaint filed by another international rather a local Indian company.

The challenge to GSK's patent was launched by an Indian subsidiary of German health group Fresenius. It had disputed the patents both for the original molecule and Tykerb.

"We are pleased that the Intellectual Property Appellate Board in India has upheld our basic patent for the lapatinib compound, the active ingredient in Tykerb," said a GSK official who did not wish to be named.

"We are, however, disappointed that the board has revoked our later expiring (in 2021) for the lapatinib ditosylate salt," the official said, adding GSK was considering an appeal.

Western drug-makers are seeking to win a larger part of India's rapidly expanding drugs market, valued at around $13 billion, to compensate for slowing sales in advanced markets.

But they say that India fails to respect intellectual property rights.

"Intellectual property protection is an important aspect in ensuring innovation is encouraged and appropriately rewarded," the GSK official said.

India earlier did not grant drug patents but resumed awarding them in 2005 as part of a World Trade Organization agreement.

add to favorites email to friend print save as pdf

Related Stories

Drug maker Novartis loses India patent battle (Update)

Apr 01, 2013

India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world ...

India generics giant wins cancer drug patent case

Sep 08, 2012

Indian generics giant Cipla says it has scored a "landmark" court win in a patent challenge launched by Switzerland's Roche Holding over the Mumbai firm's version of a lung-cancer drug.

Bayer challenges India cancer drug ruling

May 06, 2012

German pharmaceutical giant Bayer AG has challenged a ground-breaking Indian ruling that allowed a local firm to produce a vastly cheaper copy of its patented drug for kidney and liver cancer.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments